Media Kit

Albert D. Friesen holds a Ph.D. in protein chemistry from the University of Manitoba. He has been instrumental in the founding and development of several health industry companies, including ABI Biotechnology (now Apotex Fermentation), Canada's first profitable biotech company, and the Winnipeg Rh Institute, where he led the development of Canada's first biotech product, WinRho. Dr. Friesen has also played a key role in a number of regional and national organizations, including a founder and first Board of Director Chair of the Industrial Biotechnology Association of Canada (now BIOTECanada). He is President and founder of Genesys Venture Inc. (GVI), which provides the expertise for launching and managing emerging health and biotechnology ventures. He has served as CEO and Chair of Medicure Inc. since he led its formation in 1997.

Dr. Neil Owens is responsible for implementing Medicure's strategic plans and overseeing day-to-day operations including the advancement and management of new and existing pharmaceutical products. Dr. Owens has worked with Medicure since 2014, serving in various positions of escalating responsibility within Medical Affairs, and most recently as Director, Scientific Affairs. His responsibilities have included providing scientific input and expertise to support manufacturing, product development and clinical studies, as well as KOL engagement and team management. Dr. Owens holds a Bachelor of Science and a Ph.D. in Chemistry from the University of Manitoba and has Postdoctoral experience with the European Institute of Chemistry and Biology (Bordeaux, France). His research background has focused on organic & medicinal chemistry, and overall the application of science towards solving health-related issues.

Dr. Reuben Saba is the Vice President of Scientific and Medical Affairs for Medicure Inc. and directs, manages and coordinates all activities within these departments. At Medicure, Dr. Saba was involved in commercial launch of the High Dose Bolus (HDB) Regimen of Aggrastat® (tirofiban hydrochloride) injection in 2014, Zypitamag™ (pitvastatin) in 2018 and Remote Dielectric Sensing (ReDS™) Technology in 2019. Dr. Saba began his tenure at Medicure as a Medical Science Liaison in the U.S. Midwest Regions and soon became the Regional Medical Affairs Manager in 2015 for the US Midwest and Northeast regions. Dr. Saba became the Director of Medical Affairs, Medical Information and Medical-Technical Marketing in 2019 prior to accepting his current role. Before joining Medicure Inc., Dr. Saba worked at the Public Health Agency of Canada (PHAC) in the Molecular Pathobiology Department focusing on the host genetics involved in prion pathobiology. Dr. Saba obtained his MSc and PhD at the University of Manitoba and completed post-doctoral training at the Interdisciplinary Center for Neurosciences (IZN) at the University of Heidelberg (Heidelberg, Germany). At IZN, Dr Saba's focus was on the neurobiology of addiction. Dr. Saba is well published and was a recipient of several merit-based fellowships.

David Gurvey is an accomplished finance leader with an established track record of strong financial stewardship and strategically building company value. He previously held the position of Chief Financial Officer for DiaMedica Therapeutics, where he was involved in key strategic transactions contributing to growth in company value from $2.4 million to $40 million. He has the capabilities and qualifications to accelerate Medicure's growth and business strategy.